Overview
Acute Myeloid Leukemia (AML) is the most common and fatal acute leukemia in adults. Tyrosine kinase inhibitors (TKIs) have shown some promise in clinical trials, however, the real-world survival outcomes of patients with AML treated with TKIs are less understood.
This study examined 482 adults with AML treated with FLT3- or IDH-targeted TKIs from the nationwide Flatiron Health electronic health record-derived de-identified database, revealing overall poor survival outcomes regardless of treatment timing . Younger age, favorable ELN 2017 risk classification, receiving a prior stem cell transplant, and having commercial insurance were linked to better survival.
Why this matters
Through real-world data, these findings highlighted the continued need for more effective treatment strategies and further investigation into factors that may improve survival for adult patients with AML.